Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

U. Sauerzopf; A. Weidenauer; I. Dajic; M. Bauer; L. Bartova; B. Meyer; L. Nics; C. Philippe; S. Pfaff; V. Pichler; M. Mitterhauser; W. Wadsak; M. Hacker; S. Kasper; R. Lanzenberger; L. Pezawas; N. Praschak-Rieder; M. Willeit

doi:10.1016/j.nicl.2021.102813

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

U. Sauerzopf
, A. Weidenauer
, I. Dajic
, M. Bauer
, L. Bartova
, B. Meyer
, L. Nics
, C. Philippe
, S. Pfaff
, V. Pichler
, M. Mitterhauser
, W. Wadsak
, M. Hacker
, S. Kasper
, R. Lanzenberger
, L. Pezawas
, N. Praschak-Rieder
, M. Willeit (Corresponding author)

Publications: Contribution to journal › Article › Peer Reviewed

Original language	English
Article number	102813
Number of pages	8
Journal	NeuroImage: Clinical
Volume	32
DOIs	https://doi.org/10.1016/j.nicl.2021.102813
Publication status	Published - 2021
Externally published	Yes

Funding

This project was funded by the Vienna Science and Technology Fund (WWTF, Grant number: CS15-033), the Austrian Science Fund (FWF, Grant number: P23585-B09), the Anniversary Fund of the Austrian National Bank (Grant number. 16723), the Medical Scientific Fund of the Mayor of the City of Vienna (Grant number 15189), all granted to M.W. Without relevance to this work, M. Willeit declares to having received speaker honoraria and consulting fees from Janssen-Cilag Pharma GmbH, Austria. Without relevance to this work, W. Wadsak declares to havingreceived speaker honoraria from GE Healthcare, research grants from IpsenPharma, Eckert-Ziegler AG, Scintomics and ITG. WW is a part time eployee ofCBmed Ltd (Center for Biomarker Research in Medicine, Graz, Austria). and is a member of advisory boards of Amgen, Chieri and Sanofi-Aventis. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. S. Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP OrphanPharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. U. Sauerzopf, A. Weidenauer, I. Dajic, M. Bauer, L. Bartova, B. Meyer, L. Nics, C. Philippe, S. Pfaff, V. Pichler, M. Mitterhauser, L. Pezawas and N. Praschak-Rieder have no conflict of interest to declare.

Austrian Fields of Science 2012

302054 Nuclear medicine

Keywords

(+)-[C]-PHNO
Dopamine
Glucose
Psychosis
BASE-LINE
TOLERANCE
METABOLIC DYSREGULATION
D-2 RECEPTORS
(+)-[C-11]-PHNO
INSULIN
POSITRON-EMISSION-TOMOGRAPHY
PHARMACOLOGY
MORTALITY GAP
ENDOGENOUS DOPAMINE
ASSOCIATION

Access to Document

10.1016/j.nicl.2021.102813Licence: CC BY 4.0

Cite this

Sauerzopf, U., Weidenauer, A., Dajic, I., Bauer, M., Bartova, L., Meyer, B., Nics, L., Philippe, C., Pfaff, S., Pichler, V., Mitterhauser, M., Wadsak, W., Hacker, M., Kasper, S., Lanzenberger, R., Pezawas, L., Praschak-Rieder, N., & Willeit, M. (2021). Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. NeuroImage: Clinical, 32, Article 102813. https://doi.org/10.1016/j.nicl.2021.102813

@article{c54c14d69b58449390f02e53bd3e843e,

title = "Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia",

keywords = "(+)-[C]-PHNO, Dopamine, Glucose, Psychosis, BASE-LINE, TOLERANCE, METABOLIC DYSREGULATION, D-2 RECEPTORS, (+)-[C-11]-PHNO, INSULIN, POSITRON-EMISSION-TOMOGRAPHY, PHARMACOLOGY, MORTALITY GAP, ENDOGENOUS DOPAMINE, ASSOCIATION",

author = "U. Sauerzopf and A. Weidenauer and I. Dajic and M. Bauer and L. Bartova and B. Meyer and L. Nics and C. Philippe and S. Pfaff and V. Pichler and M. Mitterhauser and W. Wadsak and M. Hacker and S. Kasper and R. Lanzenberger and L. Pezawas and N. Praschak-Rieder and M. Willeit",

note = "Funding Information: This project was funded by the Vienna Science and Technology Fund (WWTF, Grant number: CS15-033), the Austrian Science Fund (FWF, Grant number: P23585-B09), the Anniversary Fund of the Austrian National Bank (Grant number. 16723), the Medical Scientific Fund of the Mayor of the City of Vienna (Grant number 15189), all granted to M.W. Funding Information: Without relevance to this work, M. Willeit declares to having received speaker honoraria and consulting fees from Janssen-Cilag Pharma GmbH, Austria. Without relevance to this work, W. Wadsak declares to havingreceived speaker honoraria from GE Healthcare, research grants from IpsenPharma, Eckert-Ziegler AG, Scintomics and ITG. WW is a part time eployee ofCBmed Ltd (Center for Biomarker Research in Medicine, Graz, Austria). and is a member of advisory boards of Amgen, Chieri and Sanofi-Aventis. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. S. Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP OrphanPharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. U. Sauerzopf, A. Weidenauer, I. Dajic, M. Bauer, L. Bartova, B. Meyer, L. Nics, C. Philippe, S. Pfaff, V. Pichler, M. Mitterhauser, L. Pezawas and N. Praschak-Rieder have no conflict of interest to declare. Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

doi = "10.1016/j.nicl.2021.102813",

language = "English",

volume = "32",

journal = "NeuroImage: Clinical",

issn = "2213-1582",

}

Sauerzopf, U, Weidenauer, A, Dajic, I, Bauer, M, Bartova, L, Meyer, B, Nics, L, Philippe, C, Pfaff, S, Pichler, V, Mitterhauser, M, Wadsak, W, Hacker, M, Kasper, S, Lanzenberger, R, Pezawas, L, Praschak-Rieder, N & Willeit, M 2021, 'Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia', NeuroImage: Clinical, vol. 32, 102813. https://doi.org/10.1016/j.nicl.2021.102813

TY - JOUR

T1 - Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

AU - Sauerzopf, U.

AU - Weidenauer, A.

AU - Dajic, I.

AU - Bauer, M.

AU - Bartova, L.

AU - Meyer, B.

AU - Nics, L.

AU - Philippe, C.

AU - Pfaff, S.

AU - Pichler, V.

AU - Mitterhauser, M.

AU - Wadsak, W.

AU - Hacker, M.

AU - Kasper, S.

AU - Lanzenberger, R.

AU - Pezawas, L.

AU - Praschak-Rieder, N.

AU - Willeit, M.

N1 - Funding Information: This project was funded by the Vienna Science and Technology Fund (WWTF, Grant number: CS15-033), the Austrian Science Fund (FWF, Grant number: P23585-B09), the Anniversary Fund of the Austrian National Bank (Grant number. 16723), the Medical Scientific Fund of the Mayor of the City of Vienna (Grant number 15189), all granted to M.W. Funding Information: Without relevance to this work, M. Willeit declares to having received speaker honoraria and consulting fees from Janssen-Cilag Pharma GmbH, Austria. Without relevance to this work, W. Wadsak declares to havingreceived speaker honoraria from GE Healthcare, research grants from IpsenPharma, Eckert-Ziegler AG, Scintomics and ITG. WW is a part time eployee ofCBmed Ltd (Center for Biomarker Research in Medicine, Graz, Austria). and is a member of advisory boards of Amgen, Chieri and Sanofi-Aventis. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, Siemens Healthineers. R. Lanzenberger received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR, Heel, and support from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. S. Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP OrphanPharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. U. Sauerzopf, A. Weidenauer, I. Dajic, M. Bauer, L. Bartova, B. Meyer, L. Nics, C. Philippe, S. Pfaff, V. Pichler, M. Mitterhauser, L. Pezawas and N. Praschak-Rieder have no conflict of interest to declare. Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021

Y1 - 2021

KW - (+)-[C]-PHNO

KW - Dopamine

KW - Glucose

KW - Psychosis

KW - BASE-LINE

KW - TOLERANCE

KW - METABOLIC DYSREGULATION

KW - D-2 RECEPTORS

KW - (+)-[C-11]-PHNO

KW - INSULIN

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - PHARMACOLOGY

KW - MORTALITY GAP

KW - ENDOGENOUS DOPAMINE

KW - ASSOCIATION

UR - https://www.scopus.com/pages/publications/85114996749

U2 - 10.1016/j.nicl.2021.102813

DO - 10.1016/j.nicl.2021.102813

M3 - Article

AN - SCOPUS:85114996749

SN - 2213-1582

VL - 32

JO - NeuroImage: Clinical

JF - NeuroImage: Clinical

M1 - 102813

ER -

Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia

Funding

Austrian Fields of Science 2012

Keywords

Access to Document

Other files and links

Fingerprint

Cite this